Literature DB >> 30637502

Predicting locally advanced rectal cancer response to neoadjuvant therapy with 18F-FDG PET and MRI radiomics features.

V Giannini1,2, S Mazzetti3,4, I Bertotto3, C Chiarenza3, S Cauda5, E Delmastro6, C Bracco7, A Di Dia7, F Leone8, E Medico9, A Pisacane10, D Ribero11, M Stasi7, D Regge3,4.   

Abstract

PURPOSE: Pathological complete response (pCR) following neoadjuvant chemoradiotherapy or radiotherapy in locally advanced rectal cancer (LARC) is reached in approximately 15-30% of cases, therefore it would be useful to assess if pretreatment of 18F-FDG PET/CT and/or MRI texture features can reliably predict response to neoadjuvant therapy in LARC.
METHODS: Fifty-two patients were dichotomized as responder (pR+) or non-responder (pR-) according to their pathological tumor regression grade (TRG) as follows: 22 as pR+ (nine with TRG = 1, 13 with TRG = 2) and 30 as pR- (16 with TRG = 3, 13 with TRG = 4 and 1 with TRG = 5). First-order parameters and 21 second-order texture parameters derived from the Gray-Level Co-Occurrence matrix were extracted from semi-automatically segmented tumors on T2w MRI, ADC maps, and PET/CT acquisitions. The role of each texture feature in predicting pR+ was assessed with monoparametric and multiparametric models.
RESULTS: In the mono-parametric approach, PET homogeneity reached the maximum AUC (0.77; sensitivity = 72.7% and specificity = 76.7%), while PET glycolytic volume and ADC dissimilarity reached the highest sensitivity (both 90.9%). In the multiparametric analysis, a logistic regression model containing six second-order texture features (five from PET and one from T2w MRI) yields the highest predictivity in distinguish between pR+ and pR- patients (AUC = 0.86; sensitivity = 86%, and specificity = 83% at the Youden index).
CONCLUSIONS: If preliminary results of this study are confirmed, pretreatment PET and MRI could be useful to personalize patient treatment, e.g., avoiding toxicity of neoadjuvant therapy in patients predicted pR-.

Entities:  

Keywords:  18F-FDG PET/CT imaging; Locally advanced rectal cancer; Magnetic resonance imaging; Prediction of treatment response; Radiomics; Texture features

Mesh:

Substances:

Year:  2019        PMID: 30637502     DOI: 10.1007/s00259-018-4250-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  31 in total

1.  Preoperative versus postoperative chemoradiotherapy for rectal cancer.

Authors:  Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

2.  Index for rating diagnostic tests.

Authors:  W J YOUDEN
Journal:  Cancer       Date:  1950-01       Impact factor: 6.860

3.  Textural Parameters of Tumor Heterogeneity in ¹⁸F-FDG PET/CT for Therapy Response Assessment and Prognosis in Patients with Locally Advanced Rectal Cancer.

Authors:  Ralph A Bundschuh; Julia Dinges; Larissa Neumann; Martin Seyfried; Norbert Zsótér; Laszló Papp; Robert Rosenberg; Karen Becker; Sabrina T Astner; Martin Henninger; Ken Herrmann; Sibylle I Ziegler; Markus Schwaiger; Markus Essler
Journal:  J Nucl Med       Date:  2014-04-21       Impact factor: 10.057

4.  Assessment of tumor heterogeneity by CT texture analysis: can the largest cross-sectional area be used as an alternative to whole tumor analysis?

Authors:  Francesca Ng; Robert Kozarski; Balaji Ganeshan; Vicky Goh
Journal:  Eur J Radiol       Date:  2012-11-26       Impact factor: 3.528

5.  Tumour heterogeneity in oesophageal cancer assessed by CT texture analysis: preliminary evidence of an association with tumour metabolism, stage, and survival.

Authors:  B Ganeshan; K Skogen; I Pressney; D Coutroubis; K Miles
Journal:  Clin Radiol       Date:  2011-09-23       Impact factor: 2.350

6.  Dynamic contrast-enhanced texture analysis of the liver: initial assessment in colorectal cancer.

Authors:  Balaji Ganeshan; Katherine Burnand; Rupert Young; Chris Chatwin; Kenneth Miles
Journal:  Invest Radiol       Date:  2011-03       Impact factor: 6.016

7.  Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data.

Authors:  Monique Maas; Patty J Nelemans; Vincenzo Valentini; Prajnan Das; Claus Rödel; Li-Jen Kuo; Felipe A Calvo; Julio García-Aguilar; Rob Glynne-Jones; Karin Haustermans; Mohammed Mohiuddin; Salvatore Pucciarelli; William Small; Javier Suárez; George Theodoropoulos; Sebastiano Biondo; Regina G H Beets-Tan; Geerard L Beets
Journal:  Lancet Oncol       Date:  2010-08-06       Impact factor: 41.316

Review 8.  Radiomics: extracting more information from medical images using advanced feature analysis.

Authors:  Philippe Lambin; Emmanuel Rios-Velazquez; Ralph Leijenaar; Sara Carvalho; Ruud G P M van Stiphout; Patrick Granton; Catharina M L Zegers; Robert Gillies; Ronald Boellard; André Dekker; Hugo J W L Aerts
Journal:  Eur J Cancer       Date:  2012-01-16       Impact factor: 9.162

9.  Identification of noninvasive imaging surrogates for brain tumor gene-expression modules.

Authors:  Maximilian Diehn; Christine Nardini; David S Wang; Susan McGovern; Mahesh Jayaraman; Yu Liang; Kenneth Aldape; Soonmee Cha; Michael D Kuo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-24       Impact factor: 11.205

10.  FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0.

Authors:  Ronald Boellaard; Mike J O'Doherty; Wolfgang A Weber; Felix M Mottaghy; Markus N Lonsdale; Sigrid G Stroobants; Wim J G Oyen; Joerg Kotzerke; Otto S Hoekstra; Jan Pruim; Paul K Marsden; Klaus Tatsch; Corneline J Hoekstra; Eric P Visser; Bertjan Arends; Fred J Verzijlbergen; Josee M Zijlstra; Emile F I Comans; Adriaan A Lammertsma; Anne M Paans; Antoon T Willemsen; Thomas Beyer; Andreas Bockisch; Cornelia Schaefer-Prokop; Dominique Delbeke; Richard P Baum; Arturo Chiti; Bernd J Krause
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

View more
  39 in total

1.  Studying local tumour heterogeneity on MRI and FDG-PET/CT to predict response to neoadjuvant chemoradiotherapy in rectal cancer.

Authors:  Niels W Schurink; Simon R van Kranen; Maaike Berbee; Wouter van Elmpt; Frans C H Bakers; Sander Roberti; Joost J M van Griethuysen; Lisa A Min; Max J Lahaye; Monique Maas; Geerard L Beets; Regina G H Beets-Tan; Doenja M J Lambregts
Journal:  Eur Radiol       Date:  2021-02-10       Impact factor: 5.315

2.  Multiparametric MRI-based Radiomics approaches on predicting response to neoadjuvant chemoradiotherapy (nCRT) in patients with rectal cancer.

Authors:  Yuan Cheng; Yahong Luo; Yue Hu; Zhaohe Zhang; Xingling Wang; Qing Yu; Guanyu Liu; Enuo Cui; Tao Yu; Xiran Jiang
Journal:  Abdom Radiol (NY)       Date:  2021-07-24

3.  Value of combined multiparametric MRI and FDG-PET/CT to identify well-responding rectal cancer patients before the start of neoadjuvant chemoradiation.

Authors:  Niels W Schurink; Lisa A Min; Maaike Berbee; Wouter van Elmpt; Joost J M van Griethuysen; Frans C H Bakers; Sander Roberti; Simon R van Kranen; Max J Lahaye; Monique Maas; Geerard L Beets; Regina G H Beets-Tan; Doenja M J Lambregts
Journal:  Eur Radiol       Date:  2020-02-07       Impact factor: 5.315

4.  Adaptive Boosting (AdaBoost)-based multiwavelength spatial frequency domain imaging and characterization for ex vivo human colorectal tissue assessment.

Authors:  Shuying Li; Yifeng Zeng; William C Chapman; Mohsen Erfanzadeh; Sreyankar Nandy; Matthew Mutch; Quing Zhu
Journal:  J Biophotonics       Date:  2020-03-25       Impact factor: 3.207

5.  Predicting the tumor response to chemoradiotherapy for rectal cancer: Model development and external validation using MRI radiomics.

Authors:  Philippe Bulens; Alice Couwenberg; Martijn Intven; Annelies Debucquoy; Vincent Vandecaveye; Eric Van Cutsem; André D'Hoore; Albert Wolthuis; Pritam Mukherjee; Olivier Gevaert; Karin Haustermans
Journal:  Radiother Oncol       Date:  2019-08-17       Impact factor: 6.280

6.  Positron Emission Tomography-Based Short-Term Efficacy Evaluation and Prediction in Patients With Non-Small Cell Lung Cancer Treated With Hypo-Fractionated Radiotherapy.

Authors:  Yi-Qing Jiang; Qin Gao; Han Chen; Xiang-Xiang Shi; Jing-Bo Wu; Yue Chen; Yan Zhang; Hao-Wen Pang; Sheng Lin
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

7.  Pretreatment CT and PET radiomics predicting rectal cancer patients in response to neoadjuvant chemoradiotherapy.

Authors:  Zhigang Yuan; Marissa Frazer; Anupam Rishi; Kujtim Latifi; Michal R Tomaszewski; Eduardo G Moros; Vladimir Feygelman; Seth Felder; Julian Sanchez; Sophie Dessureault; Iman Imanirad; Richard D Kim; Louis B Harrison; Sarah E Hoffe; Geoffrey G Zhang; Jessica M Frakes
Journal:  Rep Pract Oncol Radiother       Date:  2021-02-25

8.  Diagnosing colorectal abnormalities using scattering coefficient maps acquired from optical coherence tomography.

Authors:  Yifeng Zeng; William C Chapman; Yixiao Lin; Shuying Li; Matthew Mutch; Quing Zhu
Journal:  J Biophotonics       Date:  2020-10-22       Impact factor: 3.207

9.  Structured Reporting of Rectal Cancer Staging and Restaging: A Consensus Proposal.

Authors:  Vincenza Granata; Damiano Caruso; Roberto Grassi; Salvatore Cappabianca; Alfonso Reginelli; Roberto Rizzati; Gabriele Masselli; Rita Golfieri; Marco Rengo; Daniele Regge; Giuseppe Lo Re; Silvia Pradella; Roberta Fusco; Lorenzo Faggioni; Andrea Laghi; Vittorio Miele; Emanuele Neri; Francesca Coppola
Journal:  Cancers (Basel)       Date:  2021-04-28       Impact factor: 6.639

10.  Radiomic signature of the FOWARC trial predicts pathological response to neoadjuvant treatment in rectal cancer.

Authors:  Zhuokai Zhuang; Zongchao Liu; Juan Li; Xiaolin Wang; Peiyi Xie; Fei Xiong; Jiancong Hu; Xiaochun Meng; Meijin Huang; Yanhong Deng; Ping Lan; Huichuan Yu; Yanxin Luo
Journal:  J Transl Med       Date:  2021-06-10       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.